Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two researchers from the Centre for Tropical Medicine and Global Health were awarded medals by the Royal Society of Tropical Medicine and Hygiene at the 2019 European Congress on Tropical Medicine and International Health. Professor David Warrell was awarded the Sir Patrick Manson Medal, and Dr Samson Kinyanjui the Chalmers Medal.

Professor David Warrell was awarded the Sir Patrick Manson Medal, and Dr Samson Kinyanjui the Chalmers Medal.

Professor David Warrell received the highly regarded Manson Medal, the highest prize of the Royal Society of Tropical Medicine, awarded triennially, in recognition to his lifelong work in tropical medicine, notably on malaria, snakebites and rabies. Professor Warrel not only founded the Centre for Tropical Medicine in Oxford, he started the research at the Mahidol Oxford Research Unit in Bangkok, Thailand, in 1979. His research at MORU revolutionised the treatment of severe malaria.
Professor Warrell shares the 2019 Manson Medal with Professor Janet Hemingway from the Liverpool School of Tropical Medicine. Previous award winners include Nick White (2010) and David Weatherall (1998).

Dr Samson Kinyanjui received the Chalmers Medal, awarded to researchers in tropical medicine or international health who obtained their last relevant qualification between 15 and 20 years ago. Dr Kinyanjui received this award in recognition to his work in capacity building and training of scientists in Kenya. Dr Kinyanjui is the Head of IDeAL, the Initiative to Develop African Research Leaders. IDeAL strives to attract young Africans to research and has trained 800 African researchers to date.
Previous award winners include Philip Bejon (2014), Mike English (2008), Nick Day (2006), François Nosten (2002), Bob Snow (1999), Kevin Marsh (1994), Nick White (1993) and David Warrell (1981).

Similar stories

RECOVERY Trial announced as overall winner of Best COVID-19 Response Project Award in the UK

The RECOVERY Trial has won the Project Management Institute’s Special Covid-19 UK Response Project Award. The award specifically recognised RECOVERY’s work to investigate whether the cheap steroid dexamethasone was an effective treatment for patients hospitalised with severe COVID-19.

ISARIC COVID-19 clinical database passes ½ million patient records mark

COVID-19 has exposed our vulnerability to pandemic infections and shown what works, and what does not. It has tested the effectiveness of the Oxford-based global, open-source, collaborative approach set up 10 years ago to prevent illness and deaths from infectious disease outbreaks: ISARIC, the International Severe Acute Respiratory and Emerging Infection Consortium.

Simple blood tests may help improve malaria diagnosis in clinical studies

About one-third of children diagnosed with severe malaria may instead have an alternative cause of illness, but simple blood tests could help researchers distinguish between the two and speed up research on new treatments.

RECOVERY Trial named joint winner of HDR UK’s Impact of the Year Award

The RECOVERY trial has been jointly awarded Health Data Research UK’s 2021 Impact of the Year Award. This award is open to projects which had effectively used health data to improve people’s lives, including through clinical practice, policy, software, algorithms, or publications. The award was presented by James O’Shaughnessy at HDR UK’s online Annual Scientific Conference: Data Insights in a Pandemic.

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

RECOVERY trial finds Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients who have not mounted their own immune response

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.